LXRX

Lexicon Pharmaceuticals, Inc. · NASDAQ

Performance

+4.64%

1W

+32.62%

1M

+133.96%

3M

+44.19%

6M

+62.09%

YTD

+12.73%

1Y

Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Investment Analysis Report: LXRX

Overview:

LXRX is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $778.86 million. The company's financial data provides insights into its valuation, financial health, earnings and revenue growth, profitability, operating margin, operating cash flow analysis, and...

See more ...

Technical Analysis of LXRX 2024-02-23

Overview:

In analyzing the technical indicators for LXRX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

  • Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating, indicating ...
See more ...

Recent News & Updates